Literature DB >> 29371679

A functional interplay between Δ133p53 and ΔNp63 in promoting glycolytic metabolism to fuel cancer cell proliferation.

Lu Gong1,2, Xiao Pan3, Chuan-Bian Lim1,2, Anna de Polo1,2, John B Little2, Zhi-Min Yuan4,5.   

Abstract

Although ΔNp63 is known to promote cancer cell proliferation, the underlying mechanism behind its oncogenic function remains elusive. We report here a functional interplay between ΔNp63 and Δ133p53. These two proteins are co-overexpressed in a subset of human cancers and cooperate to promote cell proliferation. Mechanistically, Δ133p53 binds to ΔNp63 and utilizes its transactivation domain to upregulate GLUT1, GLUT4, and PGM expression driving glycolysis. While increased glycolysis provides cancer cells with anabolic metabolism critical for proliferation and survival, it can be harnessed for selective cancer cell killing. Indeed, we show that tumors overexpressing both ΔNp63 and Δ133p53 exhibit heightened sensitivity to vitamin C that accumulate to a lethal level due to accelerated uptake via overexpressed GLUT1. These observations offer a new therapeutic avenue that could be exploited for clinical applications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29371679     DOI: 10.1038/s41388-017-0117-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  p53 coordinates with Δ133p53 isoform to promote cell survival under low-level oxidative stress.

Authors:  Lu Gong; Xiao Pan; Zhi-Min Yuan; Jinrong Peng; Jun Chen
Journal:  J Mol Cell Biol       Date:  2015-12-23       Impact factor: 6.216

2.  p53 directly transactivates Δ133p53α, regulating cell fate outcome in response to DNA damage.

Authors:  M Aoubala; F Murray-Zmijewski; M P Khoury; K Fernandes; S Perrier; H Bernard; A-C Prats; D P Lane; J-C Bourdon
Journal:  Cell Death Differ       Date:  2010-08-06       Impact factor: 15.828

3.  p53 isoforms can regulate p53 transcriptional activity.

Authors:  Jean-Christophe Bourdon; Kenneth Fernandes; Fiona Murray-Zmijewski; Geng Liu; Alexandra Diot; Dimitris P Xirodimas; Mark K Saville; David P Lane
Journal:  Genes Dev       Date:  2005-08-30       Impact factor: 11.361

4.  Δ113p53/Δ133p53 converts P53 from a repressor to a promoter of DNA double-stand break repair.

Authors:  Lu Gong; Jun Chen
Journal:  Mol Cell Oncol       Date:  2015-05-27

5.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

6.  TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria.

Authors:  Olav Gressner; Tobias Schilling; Katja Lorenz; Elisa Schulze Schleithoff; Andreas Koch; Henning Schulze-Bergkamen; Anna Maria Lena; Eleonora Candi; Alessandro Terrinoni; Maria Valeria Catani; Moshe Oren; Gerry Melino; Peter H Krammer; Wolfgang Stremmel; Martina Müller
Journal:  EMBO J       Date:  2005-06-09       Impact factor: 11.598

7.  The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.

Authors:  Fabiana Schwartzenberg-Bar-Yoseph; Michal Armoni; Eddy Karnieli
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

Review 8.  Somatic TP53 Mutations in the Era of Genome Sequencing.

Authors:  Pierre Hainaut; Gerd P Pfeifer
Journal:  Cold Spring Harb Perspect Med       Date:  2016-11-01       Impact factor: 6.915

9.  The Δ133p53 isoform and its mouse analogue Δ122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2.

Authors:  I Roth; H Campbell; C Rubio; C Vennin; M Wilson; A Wiles; G Williams; A Woolley; P Timpson; M V Berridge; N Fleming; M Baird; A W Braithwaite
Journal:  Oncogene       Date:  2016-03-21       Impact factor: 9.867

10.  Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Authors:  G Hofstetter; A Berger; E Schuster; A Wolf; G Hager; I Vergote; I Cadron; J Sehouli; E I Braicu; S Mahner; P Speiser; C Marth; A G Zeimet; H Ulmer; R Zeillinger; N Concin
Journal:  Br J Cancer       Date:  2011-10-18       Impact factor: 7.640

View more
  6 in total

1.  K120R mutation inactivates p53 by creating an aberrant splice site leading to nonsense-mediated mRNA decay.

Authors:  Seo-Young Lee; Jung-Hyun Park; Sangkyun Jeong; Bu-Yeo Kim; Yong-Kook Kang; Yang Xu; Sun-Ku Chung
Journal:  Oncogene       Date:  2018-10-22       Impact factor: 9.867

2.  Conformational stability and dynamics of the cancer-associated isoform Δ133p53β are modulated by p53 peptides and p53-specific DNA.

Authors:  Jiangtao Lei; Ruxi Qi; Yegen Tang; Wenning Wang; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  FASEB J       Date:  2018-12-12       Impact factor: 5.834

Review 3.  The Diverse Functions of Mutant 53, Its Family Members and Isoforms in Cancer.

Authors:  Callum Hall; Patricia A J Muller
Journal:  Int J Mol Sci       Date:  2019-12-07       Impact factor: 5.923

Review 4.  Adaptive homeostasis and the p53 isoform network.

Authors:  Sunali Mehta; Hamish Campbell; Catherine J Drummond; Kunyu Li; Kaisha Murray; Tania Slatter; Jean-Christophe Bourdon; Antony W Braithwaite
Journal:  EMBO Rep       Date:  2021-11-15       Impact factor: 8.807

Review 5.  From cancer to rejuvenation: incomplete regeneration as the missing link (part II: rejuvenation circle).

Authors:  Mamuka G Baramiya; Eugene Baranov; Irina Saburina; Lev Salnikov
Journal:  Future Sci OA       Date:  2020-06-30

6.  Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes.

Authors:  Sunali Y Mehta; Brianna C Morten; Jisha Antony; Luke Henderson; Annette Lasham; Hamish Campbell; Heather Cunliffe; Julia A Horsfield; Roger R Reddel; Kelly A Avery-Kiejda; Cristin G Print; Antony W Braithwaite
Journal:  Oncotarget       Date:  2018-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.